Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

55X_ROI_Q1_2026 May. 17 at 9:10 PM

$SLS IDMC Unblinded actual MOS and IR Data from the Interim Analysis 60th Event - told all industry participants Gps works. Industry Participants: $ABBV $RHHBY Know its not BAT AzaVEN 39 funds invested in SLS, now 160 - the market is telling anyone paying attention.\ the IDMC unblinded Cctual survival data and Immune Response data, at the 60th event, that told market participants who are Familiar and knowledgeable -- 80% Immune Response Rates .. .. is confirmed Efficacy .... MOS survival for all Pooled Patients NYM > 13.5 months for Control + patients on Gps Immunotherapy was 2x longer than Known OS for Control.

0 · Reply

55X_ROI_Q1_2026 May. 17 at 8:05 PM

$SLS SLS Announced the 60th Event, the share price Launched SLS Announced the 72nd Event, the share price Launched SLS Announced the 78th Event, the share price Launched SLS is about to announce the 80th and Final Event ... Not the results just the 80th event, the share Price will launch ahead of the Phase 3 Result, which is about 40x more valuable than the current share price. The 80th Event Puts $40B of Value on the Table. - Ballistic Verticality incoming. THE 80th EVENT PR is a A SURE THING WINNER - massive Catalyst to be Followed by an even more massive catalyst-Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.2B Manipulated Equity is worth $40B the Instant P3 Data Hits don't get conned by the reverse short con....

0 · Reply

UsingAGodAlgorithm May. 16 at 10:54 PM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA

0 · Reply

Mike22332233 May. 16 at 10:51 PM

$SLS Some think $40 Bil BO is silly ... really, FOR AN EFFECTIVE CURE FOR CANCER !!! ... and then across 20 other cancers with WT1 !!! Add in the SLS001 platform!!! ... KEYTRUDA has sales of $34 Bil per year and does NOT cure anything ... We will see how silly it is when $MRK, $ABBV and $PFE are in a bidding war to buy out $SLS ... Single BEST asymmetrical investment idea in my over 40 years investing ... ALL my profits from every other Special Situation Stock I have found (see my other posts) have been plowed back into more SLS ... If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...

4 · Reply

Mike22332233 May. 16 at 9:29 PM

$SLS PART 2 of 2 .. Even with the BAT arm at 14.7 mOS which is almost twice as long as should be expected … EFFECTIVELY, those getting GPS that had an immune response (80% of them) ARE NOT PASSING AWAY!!! ... GAME CHANGING FOR CANCER !!! When the trial ends at the 80th event, I believe you would have ALL 63 in the BAT Control arm passed away, AND ONLY 17 OF THE 63 GPS PATIENTS PASSED AWAY … 46 of the 63 will be alive and living into their 4th yr and some into their 5th year…. This has EFFECTIVELY STOPPED CANCER FROM KILLING THEM IN THIS TYPE OF CANCER !! ... There are an additional 20 or so Cancers with the WT1 within them … as I said before, likely $ABBV or $MEK or $PFE doing a BUY OUT WITHIN 3 months of the readout, and my MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) for the BO may very well be much too low if the HR is GAME-CHANGING at 0.27-0.35 ... if so, expect a bidding war and final BO at $222 !!! ... If you agree then LIKE this and FOLLOW me 👉 @Mike22332233

3 · Reply

DonVigo May. 16 at 7:30 PM

$SLS $ABBV $BMY $MRK 40 billion? You must be brain dead. Is SLS peddling a cure for cancer or a treatment? Outrageous ...!

0 · Reply

DonVigo May. 16 at 7:22 PM

$SLS $ABBV $BMY $MRK That PR event may occur under the name of a different Company. Prove me wrong! Am not new to bios. And I said "may"

0 · Reply

55X_ROI_Q1_2026 May. 16 at 7:17 PM

$SLS Does Everyone Realize Aza+VEN, BAT for Control Arm Patients, Recently FAILED 3 Large Phase 3 trials? Including Failing the VIALE-M Trial for CR1/ First Remission Maintenance. It is not complicated. GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.

0 · Reply

55X_ROI_Q1_2026 May. 15 at 8:50 PM

$SLS Hope. A beautiful Message of Hope today from our CEO. God Speed and Strength to the entire SLS Community, patients foremost - god bless the 128 Enrolled and 49 who remain, and the Dr's, Clinicians and staff, Steering Committee and IDMC and the entire SLS Corporate Team - and the Inch thick, them too. City of Hope Recruiting AML-MR Patients 35% of AML, at 4 New Locations in Atlanta, Chicago, Phoenix and Los Angeles - Fund managers, discussing SLS / GPS / SLS009 with Angelos will discover these shares stack up to a mountain of Value. 40x + Potential ROI. This AML Platform is for Sale $LLY $PFE $ABBV Gps a Safe AML Remission Maintenance Immunotherapy - Extends OS by Years - and 009 the first On Target CDk9 Inhibitor Fund Managers will continue Feasting on SLS Shares next week after the Conferences.

0 · Reply

TornadoChasers May. 15 at 5:44 PM

$ABBV they can buyout so many good ones

0 · Reply

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-14T20:15:24.000Z - 3 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

2026-05-14T11:07:12.000Z - 3 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

May 13, 2026, 2:20 PM EDT - 4 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 9 days ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 11 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

2026-05-05T12:32:52.000Z - 12 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

May 5, 2026, 8:05 AM EDT - 12 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

2026-05-04T12:13:35.000Z - 13 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

May 1, 2026, 3:05 PM EDT - 16 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 16 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 17 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

2026-04-30T18:00:46.000Z - 17 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T13:31:03.000Z - 17 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Apr 30, 2026, 9:00 AM EDT - 17 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

2026-04-30T10:15:57.000Z - 17 days ago

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:14:18.000Z - 17 days ago

AbbVie upgraded to Buy from Neutral at BofA

2026-04-29T16:41:09.000Z - 18 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:39:58.000Z - 18 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:07.000Z - 18 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T13:25:07.000Z - 18 days ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

Apr 29, 2026, 9:00 AM EDT - 18 days ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 18 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 18 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 18 days ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 19 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 19 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 20 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 24 days ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 24 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 25 days ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 25 days ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 27 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 4 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 4 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 5 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 8, 2026, 1:38 PM EDT - 5 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 5 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 5 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 5 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 6 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 6 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 6 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 6 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 6 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 6 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Feb 24, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 12:03 PM EST - 2 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 11:00 AM EST - 2 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 20, 2026, 2:00 AM EST - 3 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 19, 2026, 9:37 AM EST - 3 months ago

AbbVie Declares Quarterly Dividend

Feb 13, 2026, 10:00 AM EST - 3 months ago

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 11, 2026, 6:49 PM EST - 3 months ago

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 5:13 PM EST - 3 months ago

Abbvie sues US health agency over Botox

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Earnings Call Transcript: Q4 2025

Feb 4, 2026, 8:34 AM EST - 3 months ago

AbbVie Revenue Rises on Immunology Growth

55X_ROI_Q1_2026 May. 17 at 9:10 PM

0 · Reply

55X_ROI_Q1_2026 May. 17 at 8:05 PM

0 · Reply

UsingAGodAlgorithm May. 16 at 10:54 PM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA

0 · Reply

Mike22332233 May. 16 at 10:51 PM

4 · Reply

Mike22332233 May. 16 at 9:29 PM

3 · Reply

DonVigo May. 16 at 7:30 PM

$SLS $ABBV $BMY $MRK 40 billion? You must be brain dead. Is SLS peddling a cure for cancer or a treatment? Outrageous ...!

0 · Reply

DonVigo May. 16 at 7:22 PM

$SLS $ABBV $BMY $MRK That PR event may occur under the name of a different Company. Prove me wrong! Am not new to bios. And I said "may"

0 · Reply

55X_ROI_Q1_2026 May. 16 at 7:17 PM

0 · Reply

55X_ROI_Q1_2026 May. 15 at 8:50 PM

0 · Reply

TornadoChasers May. 15 at 5:44 PM

$ABBV they can buyout so many good ones

0 · Reply

NEWBIGTECH May. 15 at 5:18 PM

$SLS $RVMD $RHHBY $ABBV

0 · Reply

55X_ROI_Q1_2026 May. 15 at 4:41 PM

$SLS $SLS Some (idiots) say, there is No such thing, as a Sure Thing in BIO. It is a Sure thing the Algo's selling SLS Shares Down with the Sanguine Market, Have No Clue SLS is about to Announce the 80th Patient Event. Every one of Us will wish we Owned more of these SLS Shares at $7.00 when the 80th EVENT PR Hits and the Share Price Doubles, Triples or More... -- Here is an Exact Patient Cohort for the REGAL Control Arm - there are No Patients Surviving at ALL Past 16 months. - In other words, not 1 Patient remained Alive at 17 months - Aza+VEN Trial Conducted by one of $ABBV top clinicians. https://haematologica.org/article/view/11910#:~:text=Here%2C%20we%20analyze%20the%20outcomes,on%20salvage%20feasibility%20after%20relapse.

0 · Reply

55X_ROI_Q1_2026 May. 15 at 5:39 AM

$SLS $RVMD the IDMC UNBLINDED Phase 3 MOS AND IR DATA FROM THE ACTUAL INTERIM ANALYSIS. MOS and IR DATA that told all those paying attention, Gps is golden - including ABBV and BMY $RHHBY who own Aza Ven, the BAT for Control Patients. - look at the Share price / since the 60th Event was announced Dec 2024.Jan 2025: MCAP up from $77M to 1.29B - Share price up BIGLY - 160 Funds Invested up from 39 ... Look at the share Price since Dec 2025 when the 72nd Event was Announced. The 80th EVENT PR is going to launch this. for those who have no CLUE. BAT - Aza +VEN - Recently FAILED 3 Large Phase 3 Trials for AML Remission conducted by $ABBV. -- LASTLY - the 80th EVENT PR ... Is going to Launch this...

1 · Reply

himsssss May. 15 at 5:37 AM

$VKTX Just a little bit longer guys. I heard Brian Lian is getting the deal after $ABBV adds them on myspace or something according to bioloser.

1 · Reply

55X_ROI_Q1_2026 May. 15 at 1:01 AM

$SLS Little Known Fact - Gps targets WT1 - an Oncogene expressed in 97% of AML Patients. ALL AML patients regardless of Mutation are Eligible. - 3 Dr's Treating actual Patients are on record stating MOS for patients onBAT is 'dismal, not durable', 'extremely poor - 5-7 months'. - after being asked precisely how long do control patients survive in his clinical practice experience using BAT. " Median OS is just 7 months, 6-8 months. " Using Aza + VEN Aza+VEN BAT recently Failed Large Phase 3 Trials conducted by $ABBV, including 2 Ph 3 Fails for AML Remission Maintenance. VIALE-M FAILED - VIALE-T FAILED - VERONA Failed *source full transcript

0 · Reply

55X_ROI_Q1_2026 May. 15 at 12:47 AM

$SLS $RVMD for the INCH THIK MILE WIDE CREW: Gps is worth Tens of Billions. RNPV. Are you so ignorant you don't even know the IDMC UNBLINDED ACTUAL Phase 3 MOS AND IR DATA FROM THE ACTUAL INTERIM ANALYSIS. MOS and IR DATA that told all those paying attention, Gps is golden - including ABBV and BMY $RHHBY who own BAT for Control Patients. - look at the Share price / since the 60th Event was announced Dec 2024.Jan 2025: MCAP up from $77M to 1.29B - Share price up BIGLY - 160 Funds Invested up from 39 ... Look at the share Price since Dec 2025 when the 72nd Event was Announced. The 80th EVENT PR is going to launch this. for those who have no CLUE. BAT - Aza +VEN - Recently FAILED 3 Large Phase 3 Trials for AML Remission conducted by $ABBV. -- LASTLY - the 80th EVENT PR ... Is going to Launch this...

0 · Reply

55X_ROI_Q1_2026 May. 14 at 10:34 PM

$SLS focus on actual data / facts. 26 months after enrollment completed, 49 / 50 patients Remain Alive 🙏 Very Ill, Transplant Ineligible Post secondary salvage, AML Cr2 setting where the largest US REGAL clinician is on record saying 'you will not see survival past 12 months'. - 3 Dr's Treating actual Patients are on record stating MOS for patients onBAT is 'dismal, not durable', 'extremely poor - 5-7 months'. MOS and IR data from the actual Interim Analysis - was UNBLINDED. Industry Players accumulating Know. Most of the 49 or 50 REGAL Phase 3 Patients, who remain continue receive GPS Immunotherapy. - after being asked precisely how long do control patients survive in his clinical practice experience using BAT. " Median OS is just 7 months, 6-8 months. " Using Aza + VEN Aza+VEN BAT recently Failed Large Phase 3 Trials conducted by $ABBV, including 2 Ph 3 Fails for AML Remission Maintenance. VIALE-M FAILED - VIALE-T FAILED - VERONA Failed *source full transcript

0 · Reply

Wallst45 May. 14 at 9:47 PM

$ABBV nice chart 📊

0 · Reply

Iceman467 May. 14 at 8:32 PM

$ABBV drip tomorrow

0 · Reply

55X_ROI_Q1_2026 May. 14 at 6:42 PM

$SLS $LLY $ABBV BALLISTIC VERTICALITY --- in Count Down Mode. --- 80th Event may have already occurred, waiting to cycle through the data collection process. - Registrational Phase 3 Results will give Gps the Fda Green light to Generate Billions in Real Revenue Each Year - Billions of Dollars that are worth Several Tens of Billions to Big Pharma - $LLY $PFE Gps Immunotherapy will set records for patient uptake rates, 3x 4x OS Benefit for 100,000 AML Patients Currently in Remission. - Pristine Safety Profile - Easy to administer / manufacture, high margin - FDA/EU Orphan / Fast Track RPRD +200M CASH - IP Rights into 2037.

2 · Reply

55X_ROI_Q1_2026 May. 14 at 4:50 PM

$SLS $RVMD FREE MONEY. Anyone INVESTING NOW ahead of the 80th EVENT is GUARANTEED Profit. The Share Price Will be climbing a $40B Mountain of Value - until it Absolutely Launches when we get the 80th Event PR. A SURE THING WINNER - massive Catalyst to Followed by Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.2B Manipulated Equity is worth $40B the Instant P3 Data Hits

0 · Reply

55X_ROI_Q1_2026 May. 14 at 4:42 PM

$SLS FREE MONEY. Anyone Selling Shares Prior to the 80th EVENT is GIVING AWAY FREE MONEY. The Share Price Will be climbing a Mountain of Value - until it Absolutely Launches when we get the 80th Event PR. A SURE THING WINNER - massive Catalyst to Followed by Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.2B Manipulated Equity is worth $40B the Instant P3 Data Hits

2 · Reply

Market Cap	371.72B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	20.68
Forward PE	14.72
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	5,385,000
Avg Vol	6,871,812
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	70%
Beta	0.32
Analysts	Strong Sell
Price Target	$251.17